Tech Company Financing Transactions

Apellis Pharmaceuticals Funding Round

Cormorant Asset Management, Hillhouse Capital Group and venBio participated in a $47.1 million Series D funding round for Apellis Pharmaceuticals. The funding round closed on 1/6/2016.

Transaction Overview

Company Name
Apellis Pharmaceuticals
Announced On
1/6/2016
Transaction Type
Venture Equity
Amount
$47,100,000
Round
Series D
Investors

Cormorant Asset Management (Lead Investor) (Bihua Chen)

Hillhouse Capital Group (Lead Investor)

venBio (Lead Investor) (Robert Adelman)

AJU IB Investment

Epidarex Capital

Morningside Group (Gerald Chan)

Proceeds Purpose
The proceeds of the financing will be used to further advance clinical trials in the Company's ongoing complement immunotherapy programs, including paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy (GA), an advanced form of dry type age-related macular degeneration (AMD), as well as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6400 Westwind Way A
Crestwood, KY 40014
USA
Phone
(502) 241-4114
Website
www.apellis.com
Email Address
[email protected]
Overview
Apellis (NASDAQ: APLS) was founded in 2009. Apellis' approach is centered on the inhibition of the complement system, which is a cascade of interacting proteins and is an integral component of the immune system.
Profile
Apellis Pharmaceuticals LinkedIn Company Profile
Social Media
Apellis Pharmaceuticals Company Twitter Account
Company News
Apellis Pharmaceuticals News
Facebook
Apellis Pharmaceuticals on Facebook
YouTube
Apellis Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Cedric Francois
  Cedric Francois LinkedIn Profile  Cedric Francois Twitter Account  Cedric Francois News  Cedric Francois on Facebook
Chief Financial Officer
Timothy Sullivan
  Timothy Sullivan LinkedIn Profile  Timothy Sullivan Twitter Account  Timothy Sullivan News  Timothy Sullivan on Facebook
Chief Medical Officer
Federico Grossi
  Federico Grossi LinkedIn Profile  Federico Grossi Twitter Account  Federico Grossi News  Federico Grossi on Facebook
Chief Operating Officer
Pascal Deschatelets
  Pascal Deschatelets LinkedIn Profile  Pascal Deschatelets Twitter Account  Pascal Deschatelets News  Pascal Deschatelets on Facebook
VP - Finance
Nicole Perry
  Nicole Perry LinkedIn Profile  Nicole Perry Twitter Account  Nicole Perry News  Nicole Perry on Facebook
VP - General Counsel
David Watson
  David Watson LinkedIn Profile  David Watson Twitter Account  David Watson News  David Watson on Facebook
VP - Operations
Ahmad Sadr
  Ahmad Sadr LinkedIn Profile  Ahmad Sadr Twitter Account  Ahmad Sadr News  Ahmad Sadr on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/6/2016: One Medical Passport venture capital transaction
Next: 1/6/2016: Venminder venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.